Status:

COMPLETED

Confirmatory Study of OPC-12759 Ophthalmic Suspension

Lead Sponsor:

Otsuka Pharmaceutical Co., Ltd.

Conditions:

Dry Eye Syndromes

Eligibility:

All Genders

20+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to verify whether OPC-12759 ophthalmic suspension is effective compared with active control in dry eye patients.

Eligibility Criteria

Inclusion

  • Out patient
  • Subjective complaint of dry eye that has been present for minimum 20 months
  • Ocular discomfort severity is moderate to severe
  • Corneal - conjunctival damage is moderate to severe
  • Unanesthetized Schirmer's test score of 5mm/5minutes or less
  • Best corrected visual acuity of 0.2 or better in both eyes

Exclusion

  • Presence of anterior segment disease or disorder other than that associated with keratoconjunctivitis sicca
  • Ocular hypertension patient or glaucoma patient with ophthalmic solution
  • Anticipated use of any topically-instilled ocular medications or patients who cannot discontinue the use during the study
  • Anticipated use of contact lens during the study
  • Patient with punctal plug
  • Any history of ocular surgery within 12 months
  • Female patients who are pregnant,possibly pregnant or breast feeding
  • Known hypersensitivity to any component of the study drug or procedural medications
  • Receipt of any investigational product within 4 months.

Key Trial Info

Start Date :

May 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2010

Estimated Enrollment :

188 Patients enrolled

Trial Details

Trial ID

NCT00885079

Start Date

May 1 2009

End Date

April 1 2010

Last Update

December 12 2013

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Kyushu region

Kagoshima, Japan

2

Chushikoku region

Matsuyama, Japan

3

Tokai region

Nagoya, Japan

4

Kansai region

Osaka, Japan